GALT (STOCKS)
Galectin Therapeutics Inc.
$2.520000
-0.150000 (-5.62%)
Prev close: $2.670000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Joel Lewis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $173.07M
- Employees
- 15
- P/E (TTM)
- -6.39
- P/B (TTM)
- -1.30
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.08 | $-0.06 | -0.0188 | -30.72% |
|
Dec 2025 (Q4)
|
$-0.08 | $-0.10 | +0.0220 | +21.57% |
|
Sep 2025 (Q3)
|
$-0.13 | $-0.11 | -0.0178 | -15.86% |
|
Jun 2025 (Q2)
|
$-0.12 | $-0.16 | +0.0432 | +26.47% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$9.99M |
| Operating Expenses | $16.27M |
| Research and Development | $10.04M |
| Other Operating Expenses | $6.23M |
| Operating Income/Loss | -$16.27M |
| Income/Loss From Continuing Operations After Tax | -$26.25M |
| Income/Loss From Continuing Operations Before Tax | -$26.25M |
| Net Income/Loss | -$26.25M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$26.25M |
| Net Income/Loss Available To Common Stockholders, Basic | -$26.44M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $185.00K |
| Preferred Stock Dividends And Other Adjustments | $185.00K |
| Basic Earnings Per Share | -$0.41 |
| Diluted Earnings Per Share | -$0.41 |
| Basic Average Shares | 193,714,000 |
| Diluted Average Shares | 193,714,000 |
| Assets | $15.76M |
| Current Assets | $15.69M |
| Noncurrent Assets | $68.00K |
| Liabilities | $146.00M |
| Current Liabilities | $7.31M |
| Accounts Payable | $3.12M |
| Wages | $545.00K |
| Other Current Liabilities | $3.64M |
| Noncurrent Liabilities | $138.69M |
| Equity | -$131.96M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$131.96M |
| Temporary Equity | $1.72M |
| Temporary Equity Attributable To Parent | $1.72M |
| Liabilities And Equity | $15.76M |
| Net Cash Flow From Operating Activities | -$20.05M |
| Net Cash Flow From Operating Activities, Continuing | -$20.05M |
| Net Cash Flow From Financing Activities | $26.73M |
| Net Cash Flow | $7.69M |
| Net Cash Flow, Continuing | $7.69M |
| Comprehensive Income/Loss | -$26.25M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$26.25M |
| Other Comprehensive Income/Loss | $0.00 |